Trial Profile

A phase 2 trial of KER-065 for the treatment of amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Mar 2026 New trial record
09 Mar 2026 According to Keros Therapeutics media release, company announced that it has entered into an agreement with the Massachusetts General Hospital (MGH) for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (ALS) within the Healey ALS MyMatch program (ALS MyMatch), led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham.
04 Mar 2026 According to Keros Therapeutics media release, the Company plans to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com